Regarding “rib-cross thoracotomy for replacement of the thoracoabdominal or total descending aorta”  by Morishita, Kiyofumi et al.
will spontaneously seal, and secondly, to see if these intrasac flow
velocities corresponded to the preoperative branch vessel anatomy
seen on the CT angiogram. The results indicated that patients with
occluded or small inferior mesenteric arteries and fewer visualized
lumbar arteries had lower intrasac flow velocities (100 cm/sec)
and these endoleaks resolved within 6 months.1 Thus, the study
used both anatomic data from the CT and physiologic data from
the Duplex US to characterize these endoleaks.
In reference to angle correction: a 60 degree angle to flow
was used with color Doppler serving as a guide to determine the
flow channel—the aortic wall was not used as a guide for this
measurement. Assessment of flow velocities and direction was
performed in the aneurysm sac near the aneurysm wall. Where
there is no angle to flow, as when sampling at or near the lumbar
orifice, no angle correction is needed as flow is perpendicular to the
Doppler beam in this situation.
We did not measure resistive index (RI) in this study. It is
unclear to us how an appropriate RI measurement could be ob-
tained from a “to and fro” signal often associated with type II
endoleaks. We look forward to further research efforts by the
endovascular community to validate and apply these to the clinical
management of the patient with type II endoleaks.
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Regarding “Veterans Affairs (VA) Cooperative Study
#362”
The Veterans Affairs (VA) Cooperative Study #362, reported
by Willard C. Johnson and colleagues (J Vasc Surg 2002;35:413-
21), did not demonstrate any difference in patency rate for warfarin
sodium (target range, 1.4-2.8 international normalized ratio
[INR]) plus aspirin (WASA) versus aspirin (ASA) in 458 patients
after peripheral venous bypass grafting. In 373 patients with
above-knee prosthetic bypass grafts, patency was significantly bet-
ter in the WASA group (risk ratio, 0.62). These results conflict with
our findings in the Dutch Bypass Oral Anticoagulants or Aspirin
(BOA) Study,1 favoring oral anticoagulant treatment after venous
bypass grafting and ASA in patients with prosthetic grafts. There-
fore we would like to highlight the two most important differences
in the design of the two trials and to discuss some differences in
results and the implications for daily practice.
First, the degree of anticoagulation was much higher in the
Dutch BOA study: target range, 3.0 to 4.5 INR. To achieve
optimal anticoagulation the target should be within this higher
range.2 The dosage of warfarin in the VA study was monitored
once a month, compared with twice a month, on average, in the
BOA study, which may have resulted in a higher proportion of time
when degree of coagulation was within the target range. There was
also a striking difference in percentage of patients who discontin-
ued anticoagulant treatment: 40% in the VA trial versus only 14% in
the Dutch BOA study. These differences in dosage and compliance
contribute considerably to the difference in antithrombotic effi-
cacy. The difference in ASA dose (325 mg/d in VA, 80 mg/d in
BOA) probably does not explain any difference in results.3
Second, the trials differed greatly in number of patients and
duration of follow-up. The sample size in the BOA study (n 
2690) was based on expected occlusion rate after average fol-
low-up of 2 years. The large number of patient-years (4560) in the
BOA study allowed for the predefined subgroup analyses accord-
ing to type of bypass procedure and graft material.4 The VA study
comprised fewer patients (831), with 2638 patient-years of follow-
up. Sample size was based on expected 6-year patency rate. Inas-
much as most occlusions occur in the first postoperative year, the
number of patients with 1-year follow-up in the VA Study was
probably too low to demonstrate a difference between the two
treatment groups.
It was surprising that the only statistically significant difference
between the two treatment groups occurred in patients with
prosthetic above-knee bypass grafts, and favored WASA. This
difference is mainly due to a higher number of occlusions in the
ASA group in the last 3 years of the study. Given the low compli-
ance with warfarin therapy, especially over the long term, and the
small number of patients (207) in this subgroup, this effect was
probably not caused by allocated treatment but by chance or other
unknown factors.
What are the implications of the VA and BOA trials for daily
practice? The common feature of both trials is the pragmatic
design, which allows generalization of the findings to daily prac-
tice. Because of a well-organized system of Dutch Anticoagulation
Clinics, anticoagulation therapy might be more effective in The
Netherlands than in the United States. This could imply that
addition of low-dose warfarin therapy to ASA treatment in the
United States has little or no effect, whereas in the Dutch health
care setting oral anticoagulant agents are more effective than ASA
for prevention of venous graft occlusion. For patients with pros-
thetic bypass grafts, ASA remains the best antithrombotic treat-
ment, worldwide.
The authors of the VA Study have improved knowledge of
antithrombotic therapy and discussed their findings clearly. We
hope to have added further clarification with our expertise and this
contribution to the discussion.
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Regarding “Rib-cross thoracotomy for replacement of
the thoracoabdominal or total descending aorta”
In a recent issue of this journal, Dr Okita and colleagues
reported their experience with four patients in whom rib-cross
thoracotomy was performed for repair of thoracoabdominal or
entire descending aortic aneurysm (J Vasc Surg 2003;37:219-21).
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These authors stated that this thoracotomy technique provides
optimal surgical exposure without delay in early operative recovery
and without increase in postoperative morbidity. We have also
used rib-cross thoracotomy for graft replacement of the entire
descending aortic aneurysm in two patients. Like Okita and col-
leagues, we used costal coaptation pins for repair of the transected
ribs. However, although those authors reported that incision pain
in their patients was controlled within the first 2 weeks, our
patients had chronic pain that resulted in decreased mobility of the
left arm and shoulder. This required analgesic therapy for almost 1
year before relief from pain was achieved.
This experience of prolonged severe pain in our patients has
made us hesitate to use rib-cross thoracotomy, although we agree
with the authors about the excellent operative exposure of rib-
cross thoracotomy for the entire descending aorta. In our experi-
ence, however, the pain appears to offset optimal operative expo-
sure. However, inasmuch as the total number of patients, includ-
ing those operated on by us and by Dr Okita’s team, is limited,
conclusions cannot be made. We wish to alert other surgeons that
chronic pain after rib-cross thoracotomy may offset the advantages
offered by exposure in treating extensive aortic disease.
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CME tests and credits
The Journal of Vascular Surgery is now able to provide CME credits from the online version.
Visitors to the Web site are encouraged to try the tests. Access to the tests is free. If a passing grade is obtained,
CME credits are granted by the American Association for Vascular Surgery and the Society for Vascular Surgery.
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